CRSP - CIK 0001674416
CRISPR Therapeutics AG trades as CRSP and has a market capitalization of $4.77 B, making it the #1422 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.51M, down 90.6% from the prior year and net income of -$581.60M. This page tracks CRISPR Therapeutics AG through 837 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years CRISPR Therapeutics AG's revenue declined from $5.16M to $3.51M, a compound annual decline rate of 4.2%. Net profit margin compressed from -448.8% to -16569.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G/A | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-21 |
| Proxy materials | DEFA14A | 2026-04-21 |
| Proxy statement | DEF 14A | 2026-04-21 |
The largest companies sharing CRISPR Therapeutics AG's SEC industry classification (biological products, (no diagnostic substances)).
CRISPR Therapeutics AG (CRSP) has a market capitalization of $4.77 B as of 2026-06-10, ranking #1422 among US-listed companies.
CRISPR Therapeutics AG reported revenue of $3.51M for fiscal year 2025, a decrease of 90.6% year over year.
In its latest fiscal year CRISPR Therapeutics AG reported a net loss of $581.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.